Older adults struggling to follow conversations in noisy rooms may be showing the earliest signs of cognitive decline, not ...
Feb. 13 (UPI) --Regenerative medicine company Frequency Therapeutics announced Monday it will scrap development of a drug called FX-322, after testing failed to show improvement in speech perception ...
Astellas Pharma will partner with Frequency Therapeutics to develop Frequency’s lead candidate—the Phase IIa-bound sensorineural hearing loss regenerative therapeutic FX-322—through a collaboration ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate ...
Anna Baluch is a freelance writer from Cleveland, Ohio. She enjoys writing about a variety of health and personal finance topics. When she's away from her laptop, she can be found working out, trying ...
Approximately 48 million Americans have some degree of hearing loss. The average person waits seven years after first ...
An experimental regenerative therapy that Frequency Therapeutics was developing to treat a form of hearing loss has failed to beat a placebo in a clinical trial for the second time in two years, ...